126 results
10-K/A
1997 FY
EX-10.169
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
25 Nov 98
Annual report (amended)
12:00am
under the Seragen Agreements. The United States, Canada, and,
upon Ligand's appointment as exclusive wholesaler of the Products in the
European Union … , as provided for in Section 3, the European Union and the
European Union Countries (as defined in the Seragen Agreements) are referred to
collectively
CORRESP
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
3 Jan 14
Correspondence with SEC
12:00am
a 505(b)(2) in 2013 for approval in the United States and European Union to market its Captisol program. In the United States, the New Drug Application … , or NDA, for Noxafil-IV was filed and received FDA Priority Review in November 2013. In the European Union, the Marketing Authorization Application
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
26 Jul 11
Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta® PIII
12:00am
is authorized for use in all 27 member states of the European Union, as well as India, Australia, Ireland, Japan, Taiwan, Turkey, Singapore, Kuwait, Chile
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Jul 13
Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
12:00am
. In the European Union, there are approximately 37 million women suffering with osteoporosis.
“This agreement with Ethicor represents another potentially
8-K
EX-99.1
qfqoec55grbwmdnn
11 Oct 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
w44a b354rh
21 Dec 09
Regulation FD Disclosure
12:00am
425
27e48pe4hjygsrro2qw
21 Dec 09
Business combination disclosure
12:00am
8-K
EX-10.2
m4xjn
29 Apr 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
0qja3bw qni
8 Nov 11
Ligand Pharmaceuticals Announces Third Quarter Results
12:00am
8-K
EX-99
d76fq43ea4al5rouo
24 Apr 03
Financial statements and exhibits
12:00am
8-K
EX-99.1
46nnhw4
5 May 04
Financial statements and exhibits
12:00am
8-K
EX-99.1
91rexgynw7fpnu5mai
27 Oct 14
Ligand Reports Third Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
lfeaegmos9nymps
9 Feb 15
Ligand Reports Fourth Quarter and Full Year 2014 Financial Results
12:00am
8-K
EX-2.1
wipvoh65l1w56z9zv5b5
9 Aug 18
Entry into a Material Definitive Agreement
9:05am
8-K
EX-99.1
f6i b00n7gnti9
8 May 18
Ligand Reports First Quarter 2018 Financial Results
4:08pm